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Teaching session presentationsT01
Cancer and the Internet
Nicholas James, University ofBirmingham CRC Institute for Cancer Studies,
Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TT.
There has been an exponential rise in the use of the Intemet in recent years
with a proliferation ofinformation related to cancer. The potential uses ofthe
Intemet can be summarised under the following headings:
World Wide Web (WWW)
The WWW is a network of computers allowing sharing of files linked
together by "hyperlinks". It allows easy access and navigation, the main
problenm being finding good quality infornation. Increasingly, bodies such as
the National Cancer Institute in the USA are placing large bodies of
infonnation and are a very valuable resource. The WWW has a number of
uses in relation to cancer, for example:
* As an informnation resource for clinicians
* As an information resource for patients and carers
* As a iiieans ofdistributing protocols and guidelines
Electronic mail (email)
Email allows computer to computer transfer of files. As most medical and
scientific communications are now produced on word processors, cutting out
the inteninediate paper stage has potential huge advantages in terms ofspeed,
reliability and eventually cost. It is likely to largely replace fax and can
replace man) letters in the coming years.
Information databases
Resources like Medline are now available over the Intemet either with dial in
access or over the WWW. The ability to search such databases from any PC
rather than from a booked session in a library will clearly transforn our
ability to obtain up to date infornation rapidly.
Medical records
With patients frequently being managed in multiple hospitals for cancer,
extended networks such as the Intemet and NHS network offer the possibility
of a unified patient record, available wherever the patient is seen, preventing
duplication ofeffort and reducing the potential for inappropriate therapy.
T03 MY MOTHER HAD BREAST CANCER -
WHAT DO I DO? C.M. Steel. University of
St Andrews. Scotland.
Don't panic. Your risk of having inherited a breast cancer
predisposing gene is less than one in thirty. However, was your
motherexceptionally young at diagnosis ? Have there been more cases
of breast, ovarian or other relevant cancers in her family ? Do you
really know your family history of cancer ? Do you really want to
know ? Why?
If you think you may belong to a "cancer family" and want to pursue
this further, ask your GP to refer you to one of the many clinics with
a special interest in familial cancers. From a full family history,
validated via hospital records, cancer registries and death certificates,
an empirical estimate ofcancer risk can be derived.
Ifyour residual lifetime risk ofbreast cancer is over 20%, you may be
enrolled in a programme ofregular screening (by clinical examination
and mammography) starting five years earlier than the youngest age of
cancer diagnosis in an affected relative. The value ofthis approach is
still unproven but preliminary findings are encouraging.
You may be invited to take part in the first large-scale
chemoprevention trial, using tamoxifen. The concept of a double-
blind trial will be explained and you will need to decide whether this is
acceptable.
Unless your risk is extremely high, prophylactic mastectomy is
unlikely to be discussed. For a small number of women, however,
this procedure may be appropriate and can be successful in relieving
legitimate anxiety.
How do you feel about genetic testing, if and when a causal mutation
is found in your family ? This applies to few women at present but the
numbers are likely to grow as molecular screening technology
develops. Before reaching any decision you will receive counselling
so that you are aware of all the implications ofboth a positive and a
negative result.
These issues will be explored in the light of opinions gathered from
women attending breast cancer family clinics in Edinburgh and
Dundee.
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RADIOT1HFRAPY FOR THE NON - RADIOTHERAPIST
AJ 'Munro, Department ofClinical Oncology, Ninewells
Hospital and ?Medical School, Dundee DD1 9SY
Ovcr 400 o of patients with cancer will be treated with radiotherapy at
some time or another during their illness. It is therefore important for all
those who care for patients with cancer to have some idea of the
practical aspects, advantages and liritations of radiotherapy. These
issues wtll be discussed within a framework that considers radiation
therapy primarily as a loco-regional treatment and that defines the intent
of trcatment as either radical or palliative. Technical advances must be
considered within constraints imposed not only by respect for the
therapeutic ratio but also bl operational factors such as affordabihty and
ix,.ilab)ility of technical rcsources. This presentation will address many of
the nmisconceptionis concerning radiotherapy and its practitioners: that
dose is a simple concept; that there is some ideal universally applicable
radiation dose; that all techniques and policies have a scientific rationale;
that the speciality of radiation therapy is the last refuge of the
intellectual1v destitute; that the adverse effects of radiotherapy almost
ins ari.iblx outweigh its benefits; that radiation works solely by disrupting
mitosis. Bv tackling a few shibboleths, it may be possible to demonstrate
that radiotherapy is neither so simple nor so complex as it may appear to
those outwith the speciality.
T04 Recent Advances In Palliative
Medicine
J Welsh, Department of Palliative Medicine, University of
Glasgow, Beatson Oncology Centre, Western Infirmary GI1 6NT
Pain pathophysiology, receptors, opioid preparations and
formulations.
Over the past 20-30 years research in pain has increased understanding
of the pathophysiology of pain mechanisms and of peripheral and central
sensitisation. The 'wind up' phenomenon together with the dynamic and
fluid nature of the nociceptive pathway is better understood. Tolerance to
opioid side effects, partial and full cross tolerance has also been an area
of further research. This has lead to the practice of opioid rotation in
some countries. Coupled with the above refinement of knowledge of
nociceptors has lead to the use of drugs such as ketamine to block N-
methyl D-aspartate receptors. New opioid preparations continue to be
researched and developed and there now exists a spectrum of different
formulations utilising various delivery pathways.
Disease related nausea and vomiting: intestinal obstruction.
Neurophysiological advances have been made and these will be
outlined. Mention will be made of the role of acetylcholine receptors and
recognition of the growing importance of the area postrema. The
management of inoperable intestinal obstruction will be reviewed and the
role of hyoscine butylbromide and octreotide discussed.
Service/models of Care.
A brief review of the recent literature will highlight advances made in
care delivery and outline the palliative approach, contrasting this with
specialist palliative medicine.